 |
|
|
| |
48 Week Efficacy, Pharmacokinetics, and Safety of Once a Day 400 mg Nevirapine (Viramune) Extended Release Formulation for Treatment of Antiretroviral Naïve HIV-1 Infected Patients
|
| |
| |
Reported by Jules Levin
ICAAC Sept 14 2010 Boston
J. GATHE*, G. KNECHT, C. ORRELL, J. MALLOLAS, D. PODZAMCZER, B. TROTTIER, J. MORALES, T. NGUYEN, C. YONG, W. ZHANG, M. DRULAK and A. QUINSON
LIPIDS - Vienna: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (07/22/10)
1. Gazzard et al. HIV Med 2008; 9:563-608
2. EACS Guidelines 2009
http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf
3. DHHS 2009 http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
4.Thompson A et al. JAMA 2010; 304:321-333
TS = Treated set
FAS = Full analysis set
*Includes pyrexia, laboratory abnormalities, nausea, headache,
infections/infestations
TS = Treated set; FAS = Full analysis set
|
| |
|
|
|
|
|
